AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC)
Clinical trial NCT06245915 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06245915
- Sponsor
- Arsenal Biosciences, Inc.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-02-26
- Primary completion
- 2026-03-31
- Enrollment
- 37
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.